Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;10(8):1478-80.
doi: 10.4161/auto.29428. Epub 2014 Jun 12.

Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer

Andrew Poklepovic  1 , David A Gewirtz  2
Affiliations

Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer

Andrew Poklepovic et al. Autophagy. 2014 Aug.

Abstract

The premise of inhibiting autophagy to overcome resistance to chemotherapy has been investigated in 5 clinical phase I trials combining hydroxychloroquine with vorinostat, temsirolimus, temozolomide, or bortezomib. These studies have provided a number of insights relating to the tolerability of the combination treatments. In addition, these studies should provide guidance in the planning and design of future trials to directly determine whether the strategy of autophagy inhibition could prove useful in the treatment of various malignancies.

Keywords: autophagy; bortezomib; hydroxychloroquine; temozolomide; temsirolimus; vorinostat.

PubMed Disclaimer

References

    1. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014;74:647–51. doi: 10.1158/0008-5472.CAN-13-2966. - DOI - PubMed
    1. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis L, Mita A, Curiel TJ, Espitia CM, Nawrocki ST, et al. Combined Autophagy and HDAC Inhibition: A Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor Vorinostat in Patients with Advanced Solid Tumors. Autophagy. 2014 doi: 10.4161/auto.29231. In press. - DOI - PMC - PubMed
    1. Rangwala R, Chang C, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panossian J, Troxel T. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10 In press. - PMC - PubMed
    1. Rangwala R, Leone R, Chang C, Fecher L, Schuchter LM, Kramer A, Tan K-S, Hetjian DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10 In press. - PMC - PubMed
    1. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang C, Hu J, et al. A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme. Autophagy. 2014;10 In press. - PMC - PubMed

MeSH terms

LinkOut - more resources